What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the AFFIRM study shows that natalizumab significantly reduces the probability of sustained disability progression and annualized relapse rates compared to placebo, with hazard ratios indicating a strong clinical effect. However, the lack of direct comparisons with beta interferon and glatiramer acetate limits the robustness of the evidence for the suboptimal therapy group.
Does the economic case hold at the expected price? — Cost effectiveness
The ICERs for natalizumab compared to beta interferon and best supportive care are within acceptable ranges, suggesting it is marginally cost-effective. However, the committee expressed concerns about the potential overestimation of ICERs due to uncertainties in the model.
Is there quality-of-life evidence payers weigh? — Quality of life
Natalizumab demonstrated significant improvements in health-related quality of life as measured by the SF-36 instrument, although results were not consistent across all measures, indicating moderate but meaningful gains.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Natalizumab has a very good safety profile, with no higher incidence of adverse events compared to placebo and a statistically significant reduction in certain adverse events compared to beta interferon.
Was the drug compared against what payers expect? — Comparator Selection
The manufacturer used indirect comparisons with beta interferon and glatiramer acetate, which were not ideal due to the lack of direct evidence. The committee noted that the comparators were not fully representative of the RES group.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included a relevant subgroup of patients with highly active relapsing-remitting multiple sclerosis, although there are concerns regarding the generalizability of findings to the suboptimal therapy group.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Natalizumab can be integrated into existing care pathways with minor adjustments, as it is administered in a familiar setting (intravenous infusion) and does not require extensive new infrastructure.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact is manageable, and the therapy is expected to provide significant benefits relative to its costs, although there are concerns about the overall resource burden.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily based on the robust AFFIRM study and supported by additional data, although there are some methodological concerns regarding the indirect comparisons.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and cost-effectiveness due to reliance on indirect comparisons and assumptions in the economic model.
